Effect of Amobarbital Sodium Combined With Low-dose Propofol on Hemodynamics During Induction and Perioperative Adverse Reactions in Gynecological Laparoscopic Surgery

At present, there are limited data on perioperative efficacy of barbiturates at home and abroad. The purpose of this clinical trial is to observe the effects of amobarbital sodium combined with low-dose propofol on hemodynamics during induction and perioperative adverse reactions in gynecological laparoscopic surgery patients, and to provide a more reasonable, safe and comfortable anesthesia program for female patients who undergoing laparoscopic surgery.
The main questions it aims to answer are:
whether the combination of the two results on more stable hemodynamics during induction in gynecological laparoscopic surgery patients;
whether the incidence of perioperative oxidative stress and inflammation and postoperative nausea and vomiting（ponv） improved after the use of the two combinations of anesthesia induction.
Participants will:
Induction of anesthesia with the experimental drug or placebo；
5 ml of venous blood was retained before, after, and 1 day after surgery for follow-up determination of serum associated factor levels；
To record their vital signs at any point during the anaesthetic process; Serum serological indexes related to oxidative stress and inflammation were determined. The agitation during the recovery period was recorded. The incidence and severity of ponv were recorded at 2h, 2-6h, and 6-24h postoperatively, and the use of palonosetron was also recorded.

开始日期2024-06-01

申办/合作机构

上海市同济医院

100 项与异戊巴比妥钠相关的临床结果

登录后查看更多信息

100 项与异戊巴比妥钠相关的转化医学

登录后查看更多信息

100 项与异戊巴比妥钠相关的专利（医药）

登录后查看更多信息

1,893

项与异戊巴比妥钠相关的文献（医药）

2024-08-01·Pain and Therapy

Effect of Intravenous Sodium Pentobarbital on Pain and Sensory Abnormalities in Patients with Chronic Non-Cancer Pain: Narrative Literature Review, Research Study, and Illustrative Case Reports

Article

作者: Lakha, Shehnaz Fatima ; Mailis, Angela

INTRODUCTION:

Sodium pentobarbital (SP), a short- to intermediate-acting barbiturate, has limited information in the existing literature. The objectives of this study are to describe (a) the effect of intravenous (IV) SP infusion on pain and sensory abnormalities, and (b) its utility in the diagnosis and management of patients with chronic pain.

METHODS:

A narrative review of barbiturate applications for chronic pain was followed by a pragmatic study of 176 consecutive patients admitted to an inpatient pain unit (2004-2009). We collected demographic information upon admission, diagnoses retrieved from chart review, and pain ratings and sensory abnormalities at baseline and after blinded infusion of normal saline (NS) followed by SP.

RESULTS:

The study group consisted of 83 men and 93 women (mean age 41 ± 11 years); the mean NS dose was 7.8 ± 2.3 (range 2-10 ml), the SP dose was 223.8 ± 88 mg (range 40-420), and the numeric rating scale (NRS) baseline pain score was 6.0 ± 2. The mean reduction in NRS reached both statistical and clinical significance in 150 responders to either NS/SP or SP only. Collectively, we found (a) an extremely high rate of response to IV SP irrespective of the underlying pathology, (b) greater response for pain than for sensory abnormalities (sensory gains or deficits), (c) greater response for sensory gain than for sensory deficit, and (d) greater response for allodynia than for pinprick hyperalgesia. Illustrative case reports are also presented.

DISCUSSION:

IV SP infusion is a diagnostic tool that assists in elucidating pain generators and the nature of sensory abnormalities (central vs. peripheral), with effects similar to those of IV sodium amytal. The test cannot be viewed as a tell-all diagnostic modality and must be used in conjunction with clinical judgment, investigations, and psychological reports.

2024-05-01·Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Super-selective Wada test for pre-surgical leg motor function assessment: A case report

Article

作者: Dashti, Shervin ; Sah, Jeetendra ; Kuruvilla, Alexander ; Mutchnick, Ian ; Stilp, Rebecca ; Karakas, Cemal ; Sadle, Charles J ; Karia, Samir

INTRODUCTION:

Wada test is well-known to assess lateralization of memory and language functions; however, super-selective Wada (ss-Wada) to evaluate motor leg function is rare. We present a ss-Wada test within the anterior cerebral artery (ACA) to assess the motor function of the leg.

METHODS:

Retrospective chart review.

RESULTS:

Comprehensive phase-I/II surgical evaluation revealed an ictal focus around the left post-central gyrus with immediate involvement around the left para-central regions. To avoid potential right leg motor dysfunction with the surgery, the patient underwent a ss-Wada procedure. Angiography revealed bilateral ACAs were supplied by the left A1 segment. Super-selective microcatheter injection of amobarbital into the left ACA was performed to avoid cross-filling the contralateral ACA. The ss-Wada test confirmed no right leg motor impairment. Afterward, a craniotomy with direct cortical stimulation confirmed that the left-sided ictal/peri-ictal zone had no clear leg motor function. The patient underwent disconnection of that region and remained seizure-free at 10-month post-op follow-up without any motor or sensory deficits in the right limbs.

CONCLUSION:

This case demonstrates the proof of concept for ss-Wada in assessing lower extremity motor function. The ss-Wada procedure accurately predicted no motor deficits in the right leg, consistent with preserved motor function post-surgery.

2024-01-01·Methods in molecular biology (Clifton, N.J.)

Analysis of Barbiturates in Urine by LC-MS/MS

Article

作者: Horne, Hunter ; Ketha, Hemamalini ; Janis, Gregory ; Campbell, Matthew

In the method described here, an aliquot of a urine sample is analyzed to detect barbiturates through dilution and ultra-high-performance chromatography-tandem mass spectrometry (UPLC-MS/MS) using deuterated internal standards. This assay detects the presence of nine barbiturate drugs-amobarbital, barbital, butalbital, butabarbital, mephobarbital, secobarbital, pentobarbital, phenobarbital, and thiopental. This protocol describes two LC separation methods-first LC method (2.2 min/sample) is intended to be used as a first step of the analysis that does not separate amobarbital and pentobarbital, and a second, longer (2.7 min/sample) LC method is intended to be used only for samples which have a peak in the amobarbital/pentobarbital retention time on the shorter LC method. Since the frequency at which amobarbital and pentobarbital are observed in clinical populations is low, the shorter LC method helps gain efficiency in a high-volume laboratory environment. Additional features of this protocol that help in efficiency gain are automated extraction using Hamilton™ liquid handling system and algorithmic data review using Ascent™ software.

项与异戊巴比妥钠相关的新闻（医药）

2024-05-17

·米内网

【关注】75个品种拟新增进院，华润、扬子江、华邦......

精彩内容日前，四川省成都市妇女儿童中心医院发布公告称，拟公开引进75款新药以满足临床用药需求，包括66款化学药、6款生物药和3款中成药；其中，独家品种（含独家剂型）占比超过三成，涉及扬子江药业、华润医药、华邦制药、罗氏等知名药企。来源：成都市妇儿中心医院官网按治疗大类统计，此次成都市妇儿中心医院拟引进的药物以神经系统药物为主，占据21个席位；抗肿瘤和免疫调节剂、皮肤病用药分别占8个和7个；感觉系统药物、呼吸系统用药、消化系统及代谢药以及心脑血管系统药物各有5个产品在列。75个拟引进的药品中，独家品种有23个，占比超过三成；其中化学药有16个，生物药有4个，中成药有3个，涉及扬子江药业的神曲消食口服液、华润医药的示踪用盐酸米托蒽醌注射液、重庆华邦制药的萘替芬酮康唑乳膏、四川科瑞德制药的枸橼酸坦度螺酮胶囊等。神曲消食口服液是一款儿科厌食症用药，具有消食健胃、健脾理气的功效，目前已纳入全国医保乙类药目录。近年来该药在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端销售额逐年攀升，2023年收获超2.7亿元，同比增长17.27%，为儿科厌食症中成药TOP3产品。2023年中国公立医疗机构终端儿科厌食症中成药产品TOP10来源：米内网中国公立医疗机构药品终端竞争格局示踪用盐酸米托蒽醌注射液最早于2021年获批上市，是国内首款获批用于甲状腺癌、乳腺癌的淋巴示踪剂。2023年1月，该药通过谈判进入医保目录后市场实现快速放量，2023年在中国公立医疗机构终端销售额突破5千万元，同比增速达771.14%。此外，最新临床结果表明，示踪用盐酸米托蒽醌注射液还对肺癌、黑色素瘤、多发性骨髓瘤、肝癌、大肠癌、肾癌、前列腺癌等多个癌种有一定疗效，产品潜力在逐步释放。近年来中国公立医疗机构终端示踪用盐酸米托蒽醌注射液销售趋势（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局萘替芬酮康唑乳膏为外用抗真菌药，一般用于手癣、足癣、体癣以及花斑癣等各种原因导致的真菌感染。米内网数据显示，目前该药仅有重庆华邦制药1家企业拥有生产批文，2023年在中国公立医疗机构终端销售规模首破1亿元，同比涨逾22%，为皮肤病抗真菌化学药TOP2产品。来源：米内网一键检索此外，拟进院的独家品种中还包括国药集团的无水乙醇注射液、上海医药的注射用异戊巴比妥钠、四环医药的咪达唑仑口颊粘膜溶液、山西正来制药的潞党参口服液、罗氏的帕妥珠单抗注射液等，覆盖血液和造血系统药物、神经系统药物、补气补血类用药、抗肿瘤和免疫调节剂等多个治疗大类，进一步满足不同患者的临床用药需求。拟引进新药采购目录（带*为独家品种）资料来源：米内网数据库、成都市妇儿中心医院注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至5月17日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准申请上市临床申请核酸药物临床3期

2023-01-30

·Business Wire

Sleep Disorder Treatment Drugs Markets in China 2023: Demand to Grow by 5% Annually Through 2032 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Markets in China" report has been added to ResearchAndMarkets.com's offering. China's demand for Sleep Disorder Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars. Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties III. SLEEP DISORDER TREATMENT DRUGS INDUSTRY ASSESSMENTS Sleep Disorder Treatment Drugs Industry Structure Market Size Market Growth Driver Sleep Disorder Treatment Drugs Sales Volume Major Producer Facility Locations and Sales Volume Market Share of Key Producers Labor Cost Potential Entrants Major Distributors Major Foreign Investments Technology Development IV. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends V. SLEEP DISORDER TREATMENT DRUGS MARKET OUTLOOK Sleep Disorder Treatment Drugs Markets Outlook Government Regulations Health Care Insurance Industry Overview Consumer Spending Trends Northeast North Southeast Central Southwest Northwest Demographic Trends Health Care Industry Trends Hospitals and Hospital Beds VI. MARKETING STRATEGIES China Market Entry Overview China's Distribution System Sleep Disorder Treatment Drugs Distribution Channels Transportation and Freight Infrastructure Communications China's Market Entry Export to China Indirect export Direct Export License and Contract Manufacture Assembling in China Contract Manufacturing Trade Permit Investment Equity Joint Venture Contractual Joint Venture Wholly Foreign-Owned Enterprise VII. SLEEP DISORDER TREATMENT DRUGS PRODUCER DIRECTORY Sleep Disorder Treatment Drugs Producer Profiles and Directory A selection of companies mentioned in this report includes Wusuli River Pharmaceutical Group Wandashan Pharmaceutical Factory For more information about this report visit https://www.researchandmarkets.com/r/irmoip About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

2023-01-26

·Business Wire

China Sleep Disorder Treatment Drugs Industry Forecasts 2023: Demand to Grow by 5% Annually Through 2032 - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Industry Forecasts - China Focus" report has been added to ResearchAndMarkets.com's offering. This study focuses on China's Sleep Disorder Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China's society and economy. China is one of the world's major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world's fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market. Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector's economies of scale have yet to be achieved. Most domestic manufacturers lack the autonomic intellectual property and financial resources to develop their own brand name products. This new study focuses on industry trends and forecasts with historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. The analyst is one of the leading sources for up-to-date market information and research on the fastest-growing Chinese markets. We have published over 1,500 reports focusing on the Chinese markets, industry forecasts and company profiles. We provide hard-to-find market data and analyses. Our publications are intended to help international marketers identify business opportunities and promote their product sales in the Chinese markets. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties Market Trends Technology Development Market Development Major Industry Development Regional Development Enterprise Development Labor Market Development III. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends For more information about this report visit https://www.researchandmarkets.com/r/njb95-disorder?w=4 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与异戊巴比妥钠相关的药物交易

登录后查看更多信息